Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer

• Published in: PloS one Vol. 14; no. 4; p. e0214610
• Main Authors: O’Flaherty, Linda, Shnyder, Steven D., Cooper, Patricia A., Cross, Stephen J., Wakefield, James G., Pardo, Olivier E., Seckl, Michael J., Tavaré, Jeremy M.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 10.04.2019; Public Library of Science (PLoS)
• Subjects: Animals; Antineoplastic Agents, Phytogenic - pharmacology; Antineoplastic Agents, Phytogenic - therapeutic use; Biology and Life Sciences; Cancer research; Cancer treatment; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung - drug therapy; Care and treatment; Cell Line, Tumor; Cell Proliferation - drug effects; Chemotherapy; Chromosome Aberrations - drug effects; Chromosomes; Drug Synergism; Drug Therapy, Combination; Enzymes; Genetic research; Glycogen; Glycogen Synthase Kinase 3 - antagonists & inhibitors; Glycogen Synthase Kinase 3 - genetics; Glycogen Synthase Kinase 3 - metabolism; Glycogen synthesis; Humans; Lung cancer; Lung Neoplasms - drug therapy; Male; Medicine and Health Sciences; Mice; Mice, Nude; Non-small cell lung cancer; Novels; Paclitaxel - pharmacology; Paclitaxel - therapeutic use; Pemetrexed; Polysaccharides; Pyridines - pharmacology; Pyridines - therapeutic use; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; RNA Interference; RNA, Small Interfering - metabolism; Small cell lung cancer; Tumors

Glycogen synthase kinase-3 (GSK3) is over-expressed and hyperactivated in non-small cell lung carcinoma (NSCLC) and plays a role in ensuring the correct alignment of chromosomes on the metaphase plate during mitosis through regulation of microtubule stability. This makes the enzyme an attractive tar...